Investor Presentaiton
Dato-DXd New clinical study
TROPION-Breast02 study (TNBC 1L, Ph3) started in Jun 2022,
TROPION-PanTumor02 study (NSCLC/TNBC, Ph1/2, China only) started in Jul 2022
TROPION-Breast02 Ph3 study design
Locally recurrent inoperable or metastatic
TNBC 1L*
*Patients who are not candidates for PD-1/PD-L1 inhibitor therapy
randomize
N
= 600
1:1
Dato-DXd
Investigator's choice of chemo
Endpoints: PFS, OS, etc.
â– TROPION-PanTumor02 Ph1/2 study design
N = 118
Dato-DXd
Endpoints: ORR, etc.
Cohort 1: NSCLC
Daiichi-Sankyo
Cohort 2: TNBC
Possibility to add new cohorts for other tumors in the future
NSCLC: non small cell lung cancer, ORR: overall response rate, OS: overall survival, PFS: progression free survival, TNBC: triple negative breast cancer
25View entire presentation